drugset / Trial / NCT00112723

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00112723

Phase 1/2 Terminated 46 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2005-12
Primary completion
2011-02
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject alvocidib Small molecule 30 mg/m2 Intravenous
Subject alvocidib Small molecule 50 mg/m2 Intravenous